Source：The Insides Company Limited
On：4 January 2024
Organisations：The Insides Company Limited, Kebomed A/S
The Insides Company, a medical technology company focused on the development and commercialisation of novel chyme reinfusion therapy (CRT) devices for the treatment of intestinal failure, today announced KEBOMED as the exclusive partner for Denmark, Sweden, Norway and Finland following a signing of the distribution agreement.
Identifying and representing state of the art technology combined with an experienced and knowledgeable team is what has made us a success since starting almost three decades ago said Henrik Schjødt CEO of KEBOMED. “We look forward to working with centres already practicing or are interested in starting chyme reinfusion therapy for some of the most challenging patients to treat. The innovative solution developed in collaboration with clinicians by The Insides Company brings forward a practical solution to enable the benefits of chyme reinfusion therapy to be realised for very challenging patients and allowing them to continue to receive this treatment at home.
Garth Sutherland, CEO of The Insides Company, commented “we are excited by the opportunity to work throughout the Nordic region with the experienced and knowledgeable team at KEBOMED. A number of clinicians are already using The Insides System at a number of leading centres through the Nordic region and we are confident that with our new Nordic Partner, even more centres will be able to introduce our technology to the benefit of their patients.
About Type II Intestinal Failure and Chyme Reinfusion Therapy
Type II intestinal failure is the inability of the gut to absorb necessary water, macronutrients, micronutrients, and electrolytes to sufficiently sustain life without intravenous supplementation or replacement. This can be due to malabsorption (small bowel mucosal disease), surgical resection (short bowel syndrome), fistulae, dysmotility, or mechanical obstruction. Under the standard care pathway, patients recovering from colorectal surgery often have an enterostomy created to divert intestinal contents (chyme) away from the surgical site as it heals. The enterostomy is typically left open for 6-12 months, and during this time the chyme that is collected is disposed of, which can result in intestinal failure and other complications. The Insides System is a purpose-built medical device for performing chyme reinfusion therapy. Chyme reinfusion is a practice in the management of patients with high-output enterocutaneous fistulas, and high-output enterostomies.
About KEBOMED
KEBOMED is a leading independent European distributor of medical devices and equipment for the healthcare system with vast clinical experience and a deep knowledge of the local markets. The company of today was created in 1995 with local presence in Denmark, Sweden, Norway and Finland. KEBOMED continue to expand and have merged with & acquired medical device distributors having unique positions in other markets across Europe.
About The Insides Company
The Insides Company has commercialised 30 years of clinical experience in gut nutrition into breakthrough medical devices. The Insides Company’s mission is to provide universal access to chyme reinfusion therapy through revolutionary products and education to establish a new standard of care.
Contacts
KEBOMED A/S
Lars Poulsen, Nordic Business Manager
Telephone：+45 36 39 80 80
Email：info@kebomed.com
www.kebomed.com
The Insides Company
Mark Harvie, Consultant
Telephone：+44 7970 546778
Email：sales@theinsides.co
.png){kind=small}
